NIH-funded research R01 grant

Understanding blood vessel disorders caused by GNAQ mutations

Official title: Pathogenesis of Vascular Anomalies with GNAQ mutations

Funded at Cincinnati Childrens Hosp Med Ctr · NIH-11062365 · Data updated 2026-11-12

This study is looking at how changes in a specific gene can cause serious blood vessel problems that might lead to disfigurement or life-threatening issues, and it aims to find new treatments that could help people with these conditions.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionCincinnati Childrens Hosp Med Ctr
NIH-funded
Lab location1 site (Cincinnati, United States)
Project startApril 1, 2024
Project endMarch 31, 2028
Funding year2025
Award (this year)$593,585
NIH project number5R01HL167700-02
Project IDNIH-11062365 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are patients with vascular anomalies linked to GNAQ mutations, particularly those experiencing severe symptoms or complications.

Less likely to help

Patients without GNAQ mutations or those with unrelated vascular disorders may not benefit from this research.

What this research studies

This research investigates the genetic mutations in the GNAQ gene that lead to vascular anomalies, which can cause severe disfigurement and life-threatening conditions like Kasabach-Merritt Phenomenon. By creating a transgenic mouse model that mimics these conditions, the researchers aim to explore the underlying cellular and molecular mechanisms of these disorders. They will also test potential therapies, such as the MEK/ERK inhibitor Trametinib, to evaluate their effectiveness in treating affected patients. The study will utilize innovative models to advance understanding and treatment options for these complex vascular diseases.

Why it matters

Potential benefit: If successful, this research could lead to targeted therapies that significantly improve the quality of life and health outcomes for patients with GNAQ-related vascular anomalies.

How similar studies have gone: While this specific approach is novel, similar research has shown promise in targeting genetic mutations to develop effective therapies for vascular disorders.

Where this research is happening

  • Cincinnati Childrens Hosp Med Ctr
    Cincinnati, United States
    Active

Researchers

  • Principal investigator: Boscolo, Elisa — Cincinnati Childrens Hosp Med Ctr
  • Study coordinator: Boscolo, Elisa

Related research

Other NIH-funded projects on the same topics.

  • Accelerating Rheumatic Heart Disease Prevention in Uganda

    A program to find people with rheumatic heart disease in Ugandan communities and give them preventive care close to home.

    NIH research Cincinnati Childrens Hosp Med Ctr · Cincinnati, United States · NIH-11645314

  • Enhanced surveillance network to track childhood vaccines and viral infections in kids

    A nationwide pediatric surveillance network will closely watch how common viruses and vaccines affect children’s health, using standard protocols at hospital and ED sites.

    NIH research Cincinnati Childrens Hosp Med Ctr · Cincinnati, United States · NIH-11624109

  • Advancing CNS drug delivery through epigenetic tweaks

    A medical research project aims to help people with lysosomal storage disorders by improving how treatments reach the brain.

    NIH research Cincinnati Childrens Hosp Med Ctr · Cincinnati, United States · NIH-11617801

  • Spina Bifida Registry for Better Clinic Care

    A national registry project aims to improve care for people with spina bifida by collecting and sharing data from multidisciplinary clinics to guide evidence-based practices.

    NIH research Cincinnati Childrens Hosp Med Ctr · Cincinnati, United States · NIH-11616587

  • Hydroxyurea to help children with sickle cell anemia in Africa

    A pediatric study tests hydroxyurea treatment for young children with sickle cell anemia in several African countries to see if it can reduce illness and improve health.

    NIH research Cincinnati Childrens Hosp Med Ctr · Cincinnati, United States · NIH-11606512

  • Hydroxyurea for Children with Sickle Cell in Africa

    A pilot study tests hydroxyurea in young children with sickle cell disease across several African countries to see if it can reduce illness and hospital visits.

    NIH research Cincinnati Childrens Hosp Med Ctr · Cincinnati, United States · NIH-11606510

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.